The UK and US have agreed to a significant trade agreement that will ensure zero duties on British medicine products going into the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase spending on pharmaceuticals through the National Health Service (NHS). This pledge secures that duties on these vital exports will remain at nothing for a period of 36 months.
This development comes after earlier statements to dramatically increase import taxes on branded pharmaceutical imports, with figures discussed reaching 100%.
"This arrangement with the United Kingdom reinforces the global environment for innovative medicines and brings much-needed balance to American-British drug exports," an announcement declared.
Trade Impact
Drugs are one of the UK's biggest export categories to the United States, which is clearly the biggest destination for leading companies like GSK and AstraZeneca.
Trade data show that in the one-year period leading up to last September, the UK exported medicines valued at billions to the US. This value represented 17.4% of total UK exports in that timeframe.
"This agreement secures jobs, increases capital expenditure and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Key UK Commitments
The deal includes several key changes from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to raise overall NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be restricted at 15%. In the past, repayments topped 20%.
Industry Background
The pact follows a protracted dispute between the drug companies and the ministers over medicine costs and NHS adoption.
This friction were exacerbated by claims that US consumers were charged several times more for the same drugs than people in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while major investments have been pledged toward American operations.
One official stated that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its resources over the previous ten-year period.
